The Journal of Immunology, Vol 154, Issue 8 3969-3974, Copyright © 1995 by American Association of Immunologists

ARTICLES

T lymphocytes infiltrating sites of tumor rejection and progression display identical V beta usage but different cytotoxic activities

RA Kurt, JA Park, MC Panelli, SF Schluter, JJ Marchalonis, B Carolus and ET Akporiaye
Department of Microbiology and Immunology, University of Arizona, Arizona Health Sciences Center, Tucson 85724, USA.

Most tumors grow progressively and overwhelm the host. The rare but documented cases of spontaneous regression of primary tumors are indicative of the potential of tumor-bearing hosts to develop a significant antitumor response. Because most tumors grow progressively in the host, it is not surprising that the majority of studies have focused on T lymphocytes that infiltrate these tumors. Although these studies have generated significant and useful information during the period of tumor growth, they can only speculate on the mechanisms that are involved in tumor rejection. We have used a well developed sponge model of concomitant tumor immunity that allows us to compare the immunologic events that occur during tumor progression vs rejection. In this model, an animal harboring a primary EMT6 mammary tumor is challenged with a secondary tumor implant through a pre-implanted gelatin sponge. During the manifestation of concomitant tumor immunity, the secondary tumor is rejected and the effector cells mediating the response are retained within the sponge matrix. Using this model we analyzed the TCR usage, cytotoxic activity of lymphocytes, and cytokine production at both tumor sites. The data revealed that tumor-rejecting lymphocytes isolated from the site of secondary tumor implant were cytotoxic toward EMT6 cells, whereas tumor-infiltrating lymphocytes isolated from the progressing primary tumor were not. Interestingly, the TCR-V beta repertoire of the tumor-infiltrating lymphocytes and tumor-rejecting lymphocytes were identical with V beta 1 and V beta 8 being predominant at both sites. Furthermore, the rejection site showed higher gene expression of IFN-gamma, TNF-alpha, and IL-10 whereas TGF- beta expression was slightly higher in the progressing tumors. These findings suggest that the disparate effector functions observed during tumor progression vs rejection are not caused by different T cell phenotypes but may be due instead to influences exerted by cytokines produced at the tumor sites.

This article has been cited by other articles:

				J J MARCHALONIS, S F SCHLUTER, R T SEPULVEDA, R R WATSON, and D F LARSON Immunomodulation by Immunopeptides and Autoantibodies in Aging, Autoimmunity, and Infection Ann. N.Y. Acad. Sci., December 1, 2005; 1057(1): 247 - 259. [Abstract] [Full Text] [PDF]

				H. Tahara, K. Fujio, Y. Araki, K. Setoguchi, Y. Misaki, T. Kitamura, and K. Yamamoto Reconstitution of CD8+ T Cells by Retroviral Transfer of the TCR {alpha}{beta}-Chain Genes Isolated from a Clonally Expanded P815-Infiltrating Lymphocyte J. Immunol., August 15, 2003; 171(4): 2154 - 2160. [Abstract] [Full Text] [PDF]

				C L Chernicky, H Tan, L Yi, J R L. de Mola, and J Ilan Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo Mol. Pathol., April 1, 2002; 55(2): 102 - 109. [Abstract] [Full Text] [PDF]

				R. A. Kurt, J. A. Park, S. F. Schluter, J. J. Marchalonis, and E. T. Akporiaye TCR V{beta} usage and clonality of T cells isolated from progressing and rejected tumor sites before and after in vitro culture Int. Immunol., May 1, 2000; 12(5): 639 - 646. [Abstract] [Full Text] [PDF]

				M. Nagoshi, P. S. Goedegebuure, U. L. Burger, N. Sadanaga, M. P. Chang, and T. J. Eberlein Successful Adoptive Cellular Immunotherapy Is Dependent on Induction of a Host Immune Response Triggered by Cytokine (IFN-{gamma} and Granulocyte/Macrophage Colony-Stimulating Factor) Producing Donor Tumor-Infiltrating Lymphocytes J. Immunol., January 1, 1998; 160(1): 334 - 344. [Abstract] [Full Text] [PDF]